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Chris Boshoff, Senior Vice President of Immuno-Oncology, Translational and Early Development at Pfizer, and colleagues Samra Turajlic and 
Charles Swanton from the Francis Crick Institute and University College London give us their personal point of view on new insights and 
future therapeutic approaches for renal cancer.
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Malignant kidney tumors account for 2% of 
the global cancer burden, and its incidence 
is on the rise. In 2018, 63,000 new cases 
and 15,000 deaths due to kidney cancer will 
occur in the US and ~350,000 new cases will 
occur worldwide. There are multiple histo-
logical subtypes of renal cancer, each char-
acterized by a unique molecular landscape. 
The most common subtype, clear cell renal 
cell carcinoma (ccRCC), accounts for 75% of 
all cases and arises from the proximal tubule 
cells of the kidney nephron. The prognosis 
of patients with metastatic ccRCC is poor, 
and <10% of patients are alive 5 years after 
diagnosis.
Development and evolution
ccRCC is defined by the loss of chromosome 
3p, which is a near-ubiquitous early event 
resulting in the loss of heterozygosity in 
four tumor suppressor genes: VHL, PBRM1, 
SETD2, and BAP1. Mutation or methyla-
tion of the VHL gene is the most common 
mutational event, followed by mutations 
in PBRM1, SETD2, and BAP1. On the back-
ground of 3p loss, these mutations lead to 
bi-allelic inactivation of these genes. The 
most common cause of 3p loss is a chro-
mothripsis event, which generates a con-
current 5q gain resulting in a translocation 
t(3,5) and can occur as early as adolescence 
(Mitchell et al., 2018). Distinct evolutionary 
trajectories have been described in estab-
lished ccRCC: tumors evolving in a linear 
fashion with a limited number of driver 
events (VHL and 3p loss alone), those that 
evolve in a branched fashion resulting in 
many distinct subpopulations of cells, and 
finally tumors that are characterized by a 
punctuated burst of multiple mutational 
and copy number drivers leading to a clonal 
sweep and limited intratumor heterogene-
ity detectable by bulk multiregion sequenc-
ing (Turajlic et al., 2018a).
Sequencing of primary and metastatic 
ccRCC revealed that tumors with low ge-
netic diversity (intra-tumor heterogene-
ity [ITH]) and a low fraction of the tumor 
genome affected by somatic copy-number 
alterations (SCNAs) have an overall low 
metastatic potential and a better overall 
prognosis (Turajlic et al., 2018b). Pri-
mary tumors with high ITH are associated 
with a tempered pattern of progression 
often involving single sites of metastatic 
disease over a protracted period. In con-
trast, primary tumors with low ITH but 
elevated SCNAs appear to be associated 
with rapid progression, often to multiple 
distant sites. Early loss of chromosome 9p, 
encoding CDKN2A/B among other genes, 
also appears to predict a more aggressive 
phenotype with early-onset metastases 
and a short overall survival (Turajlic et 
al., 2018a). Future clinical studies should 
test whether adjuvant or early combinato-
rial intervention is of benefit for primary 
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Multiregion sequencing analyses revealed distinct evolutionary subtypes that are associated with distinct 
metastatic patterns. Chromosome 3p loss and VHL deficiency are nearly universal early events. Primary tu-
mors with limited ITH and a low fraction of their genome affected by SCNAs have an overall low metastatic 
potential and follow a linear pattern of evolution. Primary tumors with high ITH and high genomic instability 
follow an attenuated progression, characterized by highly branched trees and solitary metastases. These tu-
mors usually harbor early PBRM1 mutation followed by subclonal SCNAs, mutational activation of the PI3K–
AKT–mTOR pathway, or SETD2 mutation. Both chromosome 9p loss and 14q loss are late events in tumor 
evolution. In primary tumors characterized by low ITH and high genomic instability, metastatic competence 
is acquired at the early stage of tumor evolution, which then drives rapid tumor dissemination, leading to a 
poor outcome and early death from disease. In this aggressive subtype, chromosome 9p and 14q loss occurs 
early during tumor development. VHL, von Hippel-Lindau; BAP1, BRCA1-associated protein 1; PBRM1, protein 
polybromo-1; PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase; SETD2, SET domain containing 2; wGII, 
weighted genome integrity index score, measuring the extent of genome instability.
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tumors harboring 9p loss and/or low ITH 
with high SCNA.
Therapeutic approaches
Deficiency in pVHL and its E3 ligase activ-
ity results in the normoxic stabilization of 
the transcription factors hypoxia-inducible 
factor (HIF) 1α and 2α, with subsequent ac-
tivation of the vascular endothelial growth 
factor (VEGF) family, angiogenesis, tumor 
cell survival, and proliferation (Kaelin et al., 
2015). Therefore, over the last decade, small 
molecules targeting VEGF receptors (VEG 
FR inhibitors, e.g., sunitinib, cabozantinib, 
sorafenib, and pazopanib) or the anti-VEGF 
antibody (bevacizumab used in combina-
tion with low-dose INFα) have been indis-
pensable for treating advanced or metastatic 
ccRCC (Choueiri and Motzer, 2017). VEG 
FR inhibitors (e.g., axitinib, cabozantinib, 
sorafenib, or lenvatinib used in combination 
with the mammalian target of rapamycin 
[mTOR] inhibitor everolimus) are also ap-
proved for use following one prior anti-an-
giogenic treatment. Most of these oral VEG 
FR inhibitors are multi-targeted drugs, not 
only inhibiting VEG FR-1, -2, and -3, but also 
targeting related tyrosine kinases like plate-
let-derived growth factor receptor (suni-
tinib, pazopanib, sorafenib, and axitinib), 
fibroblast growth factor receptor (lenvati-
nib), or MET and AXL (cabozantinib). These 
target specificities are reflected in their 
non–cross resistance attributes (Table  1) 
and in their differentiated adverse event 
profiles. For example, increased expression 
of MET and AXL is implicated in the devel-
opment of resistance to VEG FR inhibitors in 
ccRCC preclinical models, and cabozantinib 
demonstrates significant activity after first-
line anti-angiogenic treatment.
pVHL loss is also linked to an altered 
chromatin profile that promotes ccRCC tu-
morigenesis and metastases; for example, 
VHL loss induces tumor-specific enhancer 
gains around angiogenic and metabolic 
targets through the stabilization of HIF2α/
HIF1β heterodimers (Yao et al., 2017). Pre-
clinical data support the key role for HIF2α 
in pVHL-defective ccRCC, and a human 
HIF2α genetic polymorphism is associ-
ated with an increased risk of developing 
ccRCC. Inhibition of HIF2α may result in the 
down-regulation of activated HIF2α-depen-
dent enhancer regions within ccRCC, and 
HIF2α-specific inhibitors in clinical devel-
opment may provide another targeted ther-
apeutic opportunity (Chen et al., 2016; Yao 
et al., 2017).
The FDA approval in 2015 of nivolumab 
(anti–PD-1 immune checkpoint blocker 
[ICB]) for patients with advanced ccRCC 
who have received prior anti-angiogenic 
therapy heralded a new era in the man-
agement of ccRCC (Motzer et al., 2015). 
Subsequently, it was reported in a single 
arm experience that pembrolizumab (anti–
PD-1) resulted in a 38% objective response 
rate (ORR) in first-line metastatic ccRCC 
(McDermott, D.F., et al. 2018. ASCO Annual 
Meeting. Abstract 4500). This is a noticeable 
ORR for an ICB considering that the tumor 
mutational burden (TMB) in ccRCC is low 
compared with other tumors such as mela-
noma and lung cancer. ccRCC may be an ex-
ception among tumors, where TMB does not 
correlate with ORR, suggesting that those 
genetic alterations associated with ccRCC 
Table 1. Current and investigative treatment options for advanced or metastatic renal cancer
Top: Overall survival (OS) achieved with current approved treatment options. VEG FR inhibitors used up-front for advanced or metastatic 
ccRCC result in a median OS of <30 mo. The median OS for the combination of nivolumab and the CTLA-4 blocker ipilimumab has not been 
reached yet (FDA approved for intermediate or poor-risk advanced ccRCC). At time of disease progression, an ICB or a different VEG FR 
inhibitor is indicated. The combination of a VEG FR inhibitor with an mTOR inhibitor (lenvatinib and everolimus) is also an approved treat-
ment option following one prior anti-angiogenic therapy. Bottom: ORR achieved with experimental or approved treatment options for un-
treated advanced or metastatic renal cancer. The ORRs achieved with the combination of a VEG FR inhibitor with an ICB are consistently 
>50%, although these are reported from relatively small phase 1 studies, and phase 3 randomized studies testing such combinations versus 
sunitinib are ongoing. CTLA-4, cytotoxic T lymphocyte–associated protein 4.
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yield a disproportionately higher amount 
of neoantigens and elicit robust adaptive 
immune responses. In this regard, a high 
number of frameshift insertion deletion 
mutations were reported in ccRCC, and such 
indels appear to act as potent neoantigens 
and are also associated with a high cytolytic 
CD8+ T cell expression signature (Turajlic 
et al., 2017). Other mechanisms, e.g., re-
activated endogenous retroviral elements 
(ERVs), have also been postulated to play a 
role in ccRCC immunity, and a subclass of 
ERVs whose derepression triggers innate 
immune signaling has been identified in 
certain tumors, including ccRCC (Cañadas et 
al., 2018). Discovering the high-affinity neo-
antigens enabling T cell recognition will be 
critical to further advance immunotherapy 
for ccRCC, including autologous vaccine and 
cellular approaches.
Loss of function of two genes on chro-
mosome 3p (PBRM1 and BAP1) is associated 
with an immune microenvironment and 
potentially with increased responses to ICBs 
(Miao et al., 2018). PBRM1 and BAP1 are mu-
tated in ~40% and 15% of patients, respec-
tively, and are largely non-overlapping (Voss 
et al., 2017). Truncating mutations in PBRM1 
are associated with a distinct immune-re-
lated gene expression profile. PBRM1 acts as 
a tumor suppressor gene with roles in DNA 
repair, maintenance of genome stability, 
and control of cell proliferation. BAP1 mu-
tant ccRCC tumors are also correlated with 
an inflammatory tumor microenvironment 
(Wang et al., 2018), which is noteworthy 
because BAP1 deficiency is also linked to an 
inflammatory phenotype in primary uveal 
melanoma. This inflamed subtype of ccRCC 
correlates with systemic inflammatory 
manifestations such as anemia and throm-
bocytosis, which predict a poor prognosis 
(Wang et al., 2018). These observations 
emphasize the importance of efforts to cor-
relate genetic alterations in ccRCC with out-
come and potentially develop such genetic 
features as biomarkers to select for the use 
of immunotherapy.
Anti-angiogenic therapies have been 
associated with inducing an antitumor 
microenvironment. For example, block-
ing VEGF augments intra-tumoral T cell 
infiltration, partly through vascular nor-
malization and endothelial cell activation. 
Anti-VEGF antibodies may also enhance 
the antitumor activity of ICB by promot-
ing T cell infiltration, up-regulating major 
histocompatibility complex class I expres-
sion, and reversing myeloid immunosup-
pression. Therefore, combining an ICB 
with an anti-angiogenic targeted therapy 
is a rational combination to test in the 
clinic. The ORR (Table  1) and duration of 
responses reported for such combinations 
infer that they could become a future par-
adigm for managing advanced ccRCC. The 
combination of the anti–PD-L1 ICB atezoli-
zumab with bevacizumab improves the 
clinical outcome compared with sunitinib 
in tumors enriched for T effector cells (cor-
relating with PD-L1 positivity), whereas 
sunitinib appears to be more favorable in 
highly angiogenic tumors. ICB monother-
apy is effective in tumors with pre-ex-
isting immunity and a relatively lower 
expression of myeloid inflammation–as-
sociated genes but is less effective in T 
cell–enriched tumors with concurrently 
high myeloid inflammation (McDermott 
et al., 2018). Integrating such observations 
based on cellular profiles with the genetic 
architecture of ccRCC will be essential to 
advance a precision medicine approach in 
which either an angiogenic inhibitor or an 
ICB, or a combination of these, is selected 
for advanced ccRCC. For example, VHL and 
PBRM1 mutant tumors are associated with 
both an immune profile and an angiogenic 
signature, suggesting that tumors harbor-
ing both defects could benefit most from a 
combinatorial approach. In contrast, loss 
of BAP1 associates with decreased angio-
genic signaling and an adverse outcome 
to angiogenic inhibitors, and such tumors 
may benefit mostly from an ICB (Voss et 
al., 2017). Effective combination versus se-
quencing approaches will also be critical to 
advance the overall outcome for patients 
with ccRCC.
Due to obesity and an ageing population, 
the incidence of ccRCC is predicted to in-
crease significantly during the next decade. 
During the next couple of years, we will see 
a rapidly evolving treatment paradigm, and 
treatment decision-making will become 
more multifaceted as new therapies are 
launched. As the treatment armamentar-
ium expands, including the combination of 
ICBs with angiogenic inhibitors, the need 
for predictive biomarkers to guide the use 
of such combinations versus single-agent 
approaches will become essential for treat-
ment decision-making. The detection of 
primary tumors with a linear evolutionary 
trajectory and less genomic instability may 
also infer a more wait-and-see approach. 
As the genetic events initiating and driving 
ccRCC evolution also shapes the tumor mi-
croenvironment (TME), integrating infor-
mation from the genetic architecture and 
evolutionary potential of ccRCC with the 
cellular composite of the TME and treat-
ment outcomes will be crucial to advance 
rational treatment decisions.
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